Metraipolis › archive › dc_661c8b46f7aa

Cost-utility analysis of add-on ezetimibe to moderate-intensity statin versus moderate-intensity statin alone for secondary prevention in patients with acute… — Europe PMC PMID:42244866

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42244866
DOI
10.3389/fphar.2026.1813614
License (as archived)
solo-consultazione
Archived
2026-11-01T14:01:52.361Z
SHA-256 of the archived text
070e612332dcbb29deb963dac65b1fe24354ca027051023ec9897480149c4986
Stable URL of this page
https://metraipolis.com/documento/dc_661c8b46f7aa

How to cite

Cost-utility analysis of add-on ezetimibe to moderate-intensity statin versus moderate-intensity statin alone for secondary prevention in patients with acute… — Europe PMC PMID:42244866 — Europe PMC (en), https://europepmc.org/article/MED/42244866 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_661c8b46f7aa (Metraipolis archive dc_661c8b46f7aa, sha256 070e612332dcbb29deb963dac65b1fe24354ca027051023ec9897480149c4986)
BibTeX
@misc{dc661c8b46f7aa,
  title = {Cost-utility analysis of add-on ezetimibe to moderate-intensity statin versus moderate-intensity statin alone for secondary prevention in patients with acute… — Europe PMC PMID:42244866},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42244866},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_661c8b46f7aa; sha256 070e612332dcbb29deb963dac65b1fe24354ca027051023ec9897480149c4986},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42244866. Agents can read the archived copy with the MCP tool read_document.